



27 August 2014

ASX ANNOUNCEMENT

APPENDIX 4E – FINANCIAL YEAR ENDED 30 JUNE 2014

Brisbane, Australia – **ImpediMed Limited** (ASX: IPD) (“the Company”), is pleased to provide its Appendix 4E, Preliminary Final Report for the financial year ended 30 June 2014.

ImpediMed continued its sales growth momentum recording \$3.58 million of revenue from ordinary activities for the financial year. Lymphoedema revenue grew 34% compared to the prior financial year. Full year loss reduced by \$0.53 million to \$7.94 million.

President and CEO Richard Carreon stated, “We enter financial year 2015 in a very strong position as we gear up our sales and marketing activities in preparation for the CPT® Category I code (government pay code) coming into effect on 01 Jan 2015.”

Richard Carreon
CEO

ENDS

For further information contact:

Richard Carreon, ImpediMed CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au

ImpediMed Limited - Appendix 4E
ABN 65 089 705 144
Preliminary final report

1	Current Financial Period Ended:	30 June 2014
	Previous Corresponding Reporting Period:	30 June 2013

The information contained in this document should be read in conjunction with the ImpediMed Limited Annual Financial Report for the year ended 30 June 2014 ("2014 Financial Report") and any public announcements made by ImpediMed Limited and its controlled entities during the year in accordance with continuous disclosure obligations arising under the ASX Listing Rules.

2 Results for announcement to the market

	Current reporting period \$000	Previous corresponding period \$000
2.1 Revenue from ordinary activities	\$ (3,578)	\$ (2,925)
Increase (decrease) in revenue (\$000):		\$ 653
Percentage increase (decrease):		22%
Note : Revenue related to goods and services increased for the year ended 30 June 2014 to \$3.5 million (2013 \$2.7 million), an increase of \$0.8 million year over year. The change by operating segment was an increase of \$0.6 million in medical, and a \$0.2 million increase in Test & Measurement (T&M). The \$0.6 million increase in the medical segment was due to a \$0.2 million increase in body composition and veterinary products, while total lymphoedema product revenue for the Group increased by \$0.4 million, or 34% year over year.		
2.2 Profit/(loss) from ordinary activities after tax attributable to members	(7,935)	(8,464)
Increase/(decrease) in profit from ordinary activities after tax attributable to members (\$000):		\$ 529
Percentage increase/(decrease):		6%
Note : Refer to the Directors' Report for a more extensive analysis; however, in summary, in addition to the increase in revenue above:		
- salaries and benefits expense decreased by \$0.2 million		
- rent and property costs decreased by \$0.1 million		
- travel expense increased by \$0.2 million		
- consultants and professional fees increased by \$0.1 million		
- other expense decreased by \$0.1 million		
2.3 Net profit/(loss) for the period attributable to members	(7,935)	(8,464)
Increase/(decrease) in net profit for the period attributable to members (\$000):		\$ 529
Percentage increase/(decrease):		6%
Note: Refer to 2.2 above and to the Directors' Report in the 2014 Financial Report.		

3 Dividends

3.1 Dividends

There were no dividends declared and paid during the reporting period on ordinary shares.
There were no dividends proposed and not yet recognised as a liability during the reporting period.

3.2 Dividend Record Date **Not applicable**

4 Financial Statements			
4.1 Statement of comprehensive income	Refer to the Consolidated Statement of Comprehensive Income in the 2014 Financial Report.		
4.2 Statement of financial position	Refer to the Consolidated Balance Sheet in the 2014 Financial Report.		
4.3 Statement of cash flows	Refer to the Consolidated Cash Flow Statement in the 2014 Financial Report.		
4.4 Statement of retained earnings	Refer to the Consolidated Statement of Changes in Equity in the 2014 Financial Report for movements in retained earnings.		
5 Net tangible assets per security			
	Current reporting period	Previous corresponding period	
5.1 Net tangible assets (\$000)	11,567	8,560	
Issued share capital at reporting date (\$000)	116,593	106,101	
	Current reporting period	Previous corresponding period	
Number of shares on issue at reporting date	238,672,802	181,314,055	
Net tangible assets per security	\$ 0.05	\$ 0.05	
6 Earnings per security			
	Current reporting period	Previous corresponding period	
6.1 Weighted average number of ordinary shares (excluding reserved shares) for basic earnings per share (EPS)	195,605,935	181,229,055	
Loss per share from continued operations	\$ (0.04)	\$ (0.05)	
Basic EPS	\$ (0.04)	\$ (0.05)	
Loss per share from profit attributable to ordinary shares	\$ (0.04)	\$ (0.05)	
Basic EPS	\$ (0.04)	\$ (0.05)	
Diluted earnings per share has been determined to be the same as basic earnings per share as the actual calculation is anti-dilutive for both periods presented.			
Refer to Note 12 - Earnings per share in the Annual Financial Report for the year ended 30 June 2014 for additional information pertaining to EPS for the current reporting period.			
7 Acquisitions and divestments			
There were no entities over which control has been gained or lost during the reporting period.			
8 Foreign entities			
Not applicable.			
9 Associates and joint ventures			
Not applicable.			
10 Commentary on results for the financial year			
Refer to the Annual Financial Report for the year ended 30 June 2014.			
11 Results of segments			
Refer to Note 6 - Segment reporting in the Annual Financial Report for the year ended 30 June 2014 for additional information pertaining to segment results for the current reporting period.			
12 Audited Report			
The report is based on audited accounts which are not subject to dispute, modification, or qualification.			